Abstract:Artesunate (ART), an antimalarial drug, has a broad spectrum of antitumour effects in cancer types such as esophageal and gastric cancer. However, evidence demonstrating the role of ART in cervical cancer cells is limited. In the present study, the inhibitory effect of ART on the growth of cervical cancer cells through the modulation of the cell cycle and apoptosis was investigated. The growth‐inhibitory effect of ART on a cervical cancer cell line (SiHa) was detected using a Cell Counting Kit‐8 assay after treatment with ART for 24 h, after which the half‐maximal inhibitory concentration (IC 50 ) was calculated. Using flow cytometry assays, apoptosis, the cell cycle, the levels of reactive oxygen species (ROS) and calcium (Ca 2+ ) ions, as well as the mitochondrial membrane potential were evaluated in SiHa cells following treatment with ART for 24 and 48 h. The mRNA expression levels of Bcl2, Bcl‐xl, (myeloid cell leukaemia 1) Mcl‐1, Bcl2‐like protein 11 (BIM), (Bcl2‐related ovarian killer protein) Bok, Bax and (Bcl2 homologous antagonist/killer) Bak in SiHa cells were detected using reverse transcription‐quantitative PCR. ART inhibited the growth of SiHa cells in a dose‐dependent manner. The IC 50 of ART in SiHa cells was 26.32 μg/ml. According to the IC 50 value, 15, 30 and 100 μg/ml ART were selected for further experiments, and normal saline (0 μg/ml ART) was used as the control group. The results indicated that treatment with 15, 30 and 100 μg/ml ART for 24 and 48 h induced apoptosis, increased the levels of ROS, the levels of Ca 2+ and the mRNA expression levels of BIM, Bok, Bax and Bak, but decreased the cell proliferation indices, the mitochondrial membrane potential and the mRNA expression levels of Bcl2, Bcl‐xl and Mcl‐1 in a dose‐ and time‐dependent manner. In conclusion, ART inhibited the growth of SiHa cells and induced apoptosis via a mechanism associated with the regulation of Bcl2 family member expression, which was associated with the increase of the levels of ROS and Ca 2+ and the reduction of the mitochondrial membrane potential.

Artesunate inhibits lung cancer cells via regulation of mitochondrial membrane potential and induction of apoptosis

Artesunate promotes cervical cancer cell apoptosis by regulating Bcl2 family molecules and reducing the mitochondrial membrane potential

Dihydroartemisinin sensitizes Lewis lung carcinoma cells to carboplatin therapy via p38 mitogen-activated protein kinase activation.

Artesunate-binding FABP5 promotes apoptosis in lung cancer cells via the PPARγ-SCD pathway

Dependence of Artesunate on Long Noncoding RNA‐RP11 to Inhibit Epithelial‐mesenchymal Transition of Hepatocellular Carcinoma

Anti-malarial drug: the emerging role of artemisinin and its derivatives in liver disease treatment

Artesunate promoted anti-tumor immunity and overcame EGFR-TKI resistance in non-small-cell lung cancer by enhancing oncogenic TAZ degradation

Enhanced lysosomal function is critical for paclitaxel resistance in cancer cells: reversed by artesunate

[Artesunate Suppresses Cell Proliferation of THP-1 Cells by Inducing Apoptosis].

[Artesunate upregulates the expression of CD39, CD279 and granzyme B in CD4+ and CD8+ T lymphocytes of patients with lung cancer]

Artemisinin Derivatives Inhibit Non-small Cell Lung Cancer Cells Through Induction of ROS-dependent Apoptosis/Ferroptosis

Antitumour effects of artesunate via cell cycle checkpoint controls in human oesophageal squamous carcinoma cells

Artesunate, a new antimalarial clinical drug, exhibits potent anti-AML activity by targeting the ROS/Bim and TFRC/Fe2+ pathways

Artesunate pErk up HepG2 cells to die through apoptosis in vitro

Down-regulating Effect of Artesunate on T Lymphocytes ’ Immunosuppression in Human Laryngocarcinoma Cells in Vitro

Atractylodin Induces Apoptosis and Inhibits the Migration of A549 Lung Cancer Cells by Regulating ROS-Mediated Signaling Pathways

Artesunate inhibits growth and induces apoptosis in human osteosarcoma HOS cell line in vitro and in vivo

Targeted efficacy of dihydroartemisinin for translationally controlled protein expression in a lung cancer model.

Preclinical Investigation of Artesunate As a Therapeutic Agent for Hepatocellular Carcinoma Via Impairment of Glucosylceramidase-Mediated Autophagic Degradation.

Artesunate induces autophagy dependent apoptosis through upregulating ROS and activating AMPK-mTOR-ULK1 axis in human bladder cancer cells

Artemisinin Suppresses Hepatocellular Carcinoma Cell Growth, Migration and Invasion by Targeting Cellular Bioenergetics and Hippo-YAP Signaling